Immutep Ltd
ASX:IMM

Watchlist Manager
Immutep Ltd Logo
Immutep Ltd
ASX:IMM
Watchlist
Price: 0.34 AUD
Market Cap: 494.6m AUD
Have any thoughts about
Immutep Ltd?
Write Note

Immutep Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Immutep Ltd
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Immutep Ltd
ASX:IMM
Cash from Financing Activities
AU$76m
CAGR 3-Years
13%
CAGR 5-Years
57%
CAGR 10-Years
28%
Mesoblast Ltd
ASX:MSB
Cash from Financing Activities
$40.3m
CAGR 3-Years
-28%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Cash from Financing Activities
-$1.3B
CAGR 3-Years
3%
CAGR 5-Years
-21%
CAGR 10-Years
-1%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Cash from Financing Activities
-AU$3.6m
CAGR 3-Years
-34%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Cash from Financing Activities
AU$10.2m
CAGR 3-Years
-33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Cash from Financing Activities
AU$90.2m
CAGR 3-Years
33%
CAGR 5-Years
60%
CAGR 10-Years
32%
No Stocks Found

Immutep Ltd
Glance View

Market Cap
498.5m AUD
Industry
Biotechnology

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

IMM Intrinsic Value
0.73 AUD
Undervaluation 53%
Intrinsic Value
Price

See Also

What is Immutep Ltd's Cash from Financing Activities?
Cash from Financing Activities
76m AUD

Based on the financial report for Jun 30, 2024, Immutep Ltd's Cash from Financing Activities amounts to 76m AUD.

What is Immutep Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
28%

Over the last year, the Cash from Financing Activities growth was 0%. The average annual Cash from Financing Activities growth rates for Immutep Ltd have been 13% over the past three years , 57% over the past five years , and 28% over the past ten years .

Back to Top